Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1054-1061. doi: 10.1051/medsci/2019205. Epub 2020 Jan 6.

[Immunotoxins and immunocytokines].

[Article in French; Abstract available in French from the publisher]

Author information

1
Laboratoires Pierre Fabre, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 St Julien en genevois, France.

Abstract

in English, French

Cytokines and biological toxins represent two potent classes of biomolecules that have long been explored for their potential as therapeutics. Considerable side effects and poor pharmacokinetics frequently observed with both have limited their broad application. Recombinant protein engineering has allowed the construction of immunocytokines and immunotoxins that seek to exploit the advantageous properties of immunoglobulins to address these issues. Whole antibodies, antibody fragments, constant domains and derivatives have been fused genetically to a range of cytokines and toxins. This review considers the strategies that have been employed and the problems sought to be resolved in the clinical evaluation of this class of biotherapeutic.

PMID:
31903917
DOI:
10.1051/medsci/2019205

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center